Key Highlights
- Few names embody the British "quality compounder" better than Halma.
- The FTSE 100 group, a collection of safety, environmental and healthcare technology businesses.
- Halma reported record Revenue of £2,582.3m, up 15% and through the £2.5bn mark for the first time, with organic constant-currency growth in the mid-teens supplemented by acquisitions.
- Adjusted operating profit rose 22% to £594.5m, lifting the adjusted EBIT Margin 140 basis points to 23.0%.
Few names embody the British "quality compounder" better than Halma. The FTSE 100 group, a collection of safety, environmental and healthcare technology businesses, has spent decades turning steady organic growth and bolt-on acquisitions into one of the most reliable Earnings records on the London market. Its results for the year to 31 March 2026 did nothing to dent that reputation, but with the shares long commanding a premium rating, the question investors keep returning to is whether the quality is already fully reflected in the price. The model is built to be dull in the best sense: many small, resilient niches rather than one big bet.
Record numbers across the board
Halma reported record revenue of £2,582.3m, up 15% and through the £2.5bn mark for the first time, with organic constant-currency growth in the mid-teens supplemented by acquisitions. Adjusted operating profit rose 22% to £594.5m, lifting the adjusted EBIT margin 140 basis points to 23.0%. Statutory profit before tax climbed 27% to £520.7m, while adjusted Earnings Per Share advanced 21% to 114.05p. The board proposed a total Dividend of 24.74p, up 7%, extending an extraordinary streak of 47 consecutive years of dividend growth of 5% or more, one of the longest such records in the FTSE 100 and a signal of the group's steady cash generation.
A deliberately decentralised model
Halma's strategy is unusual and deliberately unglamorous. It owns roughly 50 operating companies serving structural growth markets, hazard detection, water and environmental analysis, and medical and patient-safety devices, each run with considerable autonomy but held to demanding return targets. Growth comes from a mix of price, new products and a steady cadence of acquisitions. During the year the group completed five deals for £447m, adding two more for around £75m shortly after the year end. Research and Development spending rose 13% to £123m, or 4.7% of revenue, underpinning the pipeline of higher-margin products that management argues sustains pricing power and keeps the portfolio ahead of commoditisation.
Balance-sheet strength
The Balance Sheet remains a source of firepower rather than concern. Net Debt to adjusted EBITDA stood at 1.16x, up modestly from 0.97x but comfortably within the group's stated ceiling of around two times, leaving room for further acquisitions. Adjusted return on total invested Capital reached 16.2%, near the top of Halma's 12-17% target range, while cash conversion of 93% cleared its 90% benchmark. Total strategic Investment exceeded £600m during the year. For FY27, management guided to low double-digit percentage organic constant-currency revenue growth and margins broadly in line with the year just reported, a continuation of the formula that has served it so well.
The premium question --- and the risks
The recurring debate is valuation. Halma has historically traded on a punchy multiple of earnings, reflecting its consistency, and the key question for investors is whether continued compounding can justify that premium or whether any stumble would prompt a sharp de-rating. Risks include the pace and pricing of acquisitions in a competitive market for quality assets, integration and management succession across a sprawling portfolio, currency translation given significant overseas earnings, and sensitivity to industrial and healthcare capital-spending cycles. A richly rated share also leaves less margin for disappointment on organic growth or margins, so even a modest miss can hit the shares hard.
Outlook
Potential catalysts include the rate of bolt-on dealmaking, evidence that record R&D is translating into organic momentum, and delivery against the FY27 growth guidance. With order intake described as ahead of both revenue and the prior year, the near-term backdrop looks supportive. The longer-term test, as ever, is whether Halma's compounding machine can keep outrunning the expectations already embedded in its share price, sustaining double-digit growth from a base that grows larger and harder to move with every passing year. Management's long record has earned it the benefit of the doubt, but each incremental year of growth now demands more absolute revenue and profit than the last.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...